Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.9 SEK | +2.67% | +7.10% | +9.31% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.31% | 51.89M | |
+3.37% | 69.85B | |
+13.35% | 8.98B | |
-12.75% | 4.89B | |
+42.38% | 4.44B | |
+5.23% | 3.95B | |
+21.69% | 2.49B | |
-19.05% | 2.4B | |
-28.72% | 2.28B | |
+11.13% | 1.96B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Transcript : Orexo AB, 2023 Earnings Call, Feb 08, 2024